{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"21"}]}],"title":"≥ 2-fold Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"< 2-fold Increase"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"To determine if NHL and MM patients mobilized with G-CSF (10 µg/kg QD) plus plerixafor will have a ≥2-fold increase in circulating CD34+ cells from time 0 to 11 hours after a dose of plerixafor.","groups":[{"description":"Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma (NHL)"},{"description":"Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Multiple Myeloma (MM)"},{"description":"All patients.","id":"OG002","title":"Total"}],"paramType":"NUMBER","populationDescription":"The intent-to-treat population (defined as participants who received at least 1 dose of plerixafor).\n\nOne participant excluded from the analysis because data was missing.","reportingStatus":"POSTED","timeFrame":"Time 0 to 11 hours after the first dose of plerixafor","title":"Number of Participants Who Had a ≥ 2-fold Increase in Circulating CD34+ Cells","type":"SECONDARY","unitOfMeasure":"participants"}